Psoriasis vulgaris treatment

Empowered care and relief
for psoriasis patients


* Tämä kenttä on pakollinen



Yrityksen tiedot



Tarkentamalla syyn yhteydenottoon, voimme palvella sinua paremmin

Patient satisfaction is low1, incidence is high

Around 125 million people are affected by psoriasis worldwide, 80% of them suffer from psoriasis vulgaris2 (Pv) and studies show that only 25% of patients are satisfied with their treatment1

Psoriasis vulgaris is an incurable chronic skin disease, so plaque recurrence is lifelong. Pv plaques have a strong negative impact on the quality of life for patients suffering from this disease, encompassing functional, psychological and social aspects3. In addition, anxiety about possible side effects of treatment options such as systemic pharmaceuticals and UV light, inadequate efficacy and the efforts required by topical treatments, lead to low compliance,4, 5 which limits the success of these therapies. There is a clear need for an easier-to-use, gentler psoriasis vulgaris treatment solution.
125 million people affected by psoriasis

suffer from
psoriasis vulgaris

Only 25%
satisfied with treatment

Help your patients take control

Learn more about Philips BlueControl – wearable, gentle and clinically proven medical device for the treatment of psoriasis vulgaris.

Help your patients take control

Learn more about Philips BlueControl – wearable, gentle and clinically proven medical device for the treatment of psoriasis vulgaris.

Controlling the processes that cause symptoms


Psoriasis vulgaris plaques are caused by a highly accelerated regeneration of skin cells, specifically keratinocytes, accompanied by unregulated inflammation6. Blue LED light is proven to have both anti-proliferative7 and anti-inflammatory8 effects.

Effect of UV-free blue light in psoriasis treatment

Uncontrolled inflammation
Keratinocyte hyperproliferation
Reduced keratinocyte proliferation and enhanced differentiation
Depletion of T cells and reduced cytokine release
Blue light at a wavelength of 453 nm reduces the accelerated proliferation of keratinocytes and decreases the inflammatory response.7, 8 Clinical trials prove that this phototherapeutic approach significantly improves plaque symptoms in patients with mild to moderate psoriasis vulgaris.9, 10


When keratinocytes are exposed to blue LED light at a wavelength of 453 nm, multiplication decreases and differentiation increases. This counteracts the hyperproliferation of keratinocytes in psoriatic skin.


Blue LED light is able to deactivate immune cells such as T-cells and dendritic cells, in turn reducing cytokine release. This effect breaks the vicious cycle of self-enhancing inflammatory processes in psoriasis vulgaris.

Patient-approved, clinically proven psoriasis vulgaris treatment

Clinical investigations have been completed with positive clinical results and excellent patient satisfaction. During two key studies – 2009 and 2014 – patients with mild to moderate psoriasis vulgaris were treated with blue LED light for four weeks and three months, respectively. The first study resulted in improvement of psoriasis vulgaris plaques
9 while the second study proved the positive effects of blue LED light, especially over a longer treatment period. Compared to the untreated control plaque, the efficacy of the blue LED light therapy reduced the Local PASI significantly. 84% of patients showed an improvement in plaque symptoms, with some patients showing complete clearance of the plaque.10

In addition, treatment compliance was excellent, 98% of patients followed the treatment procedure with blue LED light over a three-month trial period. Patients reported that the treatment was convenient and the device was very user-friendly. No adverse events related to the blue light treatment were observed.10

Dr. Verena von Felbert, Department of Dermatology and Allergology at University Clinic RWTH Aachen, discusses factors that can trigger or worsen psoriasis, treatment options and important clinical research results on the therapy with blue light, and also reports on her experience with psoriasis patients using Philips BlueControl.

0 days



Treated plaque
Control plaque

Blue LED light
Potential for a range of medical applications across the health continuum

Blue light has a wavelength of 400–490 nm and is part of the light spectrum that is visible to the human eye. Blue light does not contain any UV-radiation and penetrates deeply into the skin. It is known that blue light has positive effects on the human body. LEDs are known for their energy efficiency, compact design and stability. The combination – blue LEDs – is a promising and powerful tool for medical applications. Research shows that LEDs used for medical treatments require special features that exceed those of conventional LEDs, including high intensities and tailored adjustments such as pulsed LED light. With blue LEDs optimized specifically for health applications, patients receive the benefits of phototherapy through the gentle, natural process-inducing characteristics of LED light in the visible blue spectrum.

Blue LED light therapy at a glance

  • UV-free blue LED light (453 nm) is non-toxic for the skin7, 11
  • No active ingredients or chemical substances are required
  • Avoids side effects medications may have
  • Stimulates natural processes in the body
  • LEDs are highly energy efficient, long-lasting and compact

Q&A with blue light for health expert

Why is blue light therapy effective in treating psoriasis vulgaris? How does it work and how is it different from conventional phototherapies?
Professor Matthias Born, director of clinical and scientific affairs at Philips Light & Health, shares key insights on blue LED light therapy and proof that it can be an effective way for patients to gain relief from psoriasis symptoms.

Philips BlueControl

Wearable, UV-free blue LED light phototherapy for the treatment of psoriasis vulgaris. 

Philips BlueControl

Wearable, UV-free blue LED light phototherapy for the treatment of psoriasis vulgaris.

What’s trending



44. ADF-Jahrestagung


Mar, 9 - 11
Göttingen, Germany

49.Tagung der Deutschen Dermatologischen Gesellschaft (DDG)


Apr, 26 - 29
Berlin, Germany

18ème Journées Nationales de la Société Française de Photodermatologie & Journée de Photobiologie


June, 14 - 16
Espace Vasarely, Antony France

5th Munich International Summer Academy of Practical Dermatology (ISA)


July, 25 - 29

Munich, Germany

Andrzejki Dermatologiczne


Nov, 17 - 18

Lodz, Poland

Journées Dermatologiques de Paris 2017


Dec, 12 - 16

Paris, France


  1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004; 9: 136 – 9.
  2. Parisi R, et al. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. The Society for Investigative Dermatology. J Invest Dermatol 2013;133 (2):377-85.
  3. Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U. Psychosocial consequences of psoriasis – an empirical study of disease burden in 3753 affected people. Hautarzt. 2005; 56: 466 – 72.
  4. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Archives of Dermatology. 2004; 140: 408 – 14.
  5. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. Journal of the European Academy of Dermatology & Venereology. 2006; 20: 370 – 9.
  6. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu. Rev. Pathol. Mech. Dis. 2012; 7: 385 – 422.
  7. Liebmann J, Born M, Kolb-Bachofen MV. Blue-Light Irradiation Regulates Proliferation and Differentiation in Human Skin Cells. Journal of Investigative Dermatology. 2010; 130: 259 – 269. 422.
  8. Fischer M et al. Blue light irradiation suppresses dendritic cells activation in vitro. Experimental Dermatology. 2013; 22:554 – 563.
  9. Weinstabl, A., et al. Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology, 2011; 223(3): 251 – 9.
  10. Pfaff S et al. Prospective Randomized Long-Term Study on the Efficacy and Safety of UV-Free Blue Light for Treating Mild Psoriasis Vulgaris. Dermatology, 2015; 231: 24 – 34.
  11. Awakowicz, P., et al. Biological Stimulation of the Human Skin Applying Health-Promoting Light and Plasma Sources. Contributions to Plasma Physics, 2009; 49 (9): 641 – 647.